These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32397357)

  • 1. A Role of Inflammation and Immunity in Essential Hypertension-Modeled and Analyzed Using Petri Nets.
    Formanowicz D; Rybarczyk A; Radom M; Formanowicz P
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of the renin-angiotensin and kallikrein-kinin systems to short-term variability of blood pressure in two-kidney, one-clip hypertensive rats.
    Ponchon P; Elghozi JL
    Eur J Pharmacol; 1996 Feb; 297(1-2):61-70. PubMed ID: 8851167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The vascular biology of hypertension and atherosclerosis and intervention with calcium antagonists and angiotensin-converting enzyme inhibitors.
    Pepine CJ; Handberg EM
    Clin Cardiol; 2001 Nov; 24(11 Suppl):V1-5. PubMed ID: 11712769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade.
    Tschöpe C; Schultheiss HP; Walther T
    J Cardiovasc Pharmacol; 2002 Apr; 39(4):478-87. PubMed ID: 11904521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Angiotensin II type 1 receptor on renal NAD(P)H oxidase, oxidative stress and inflammation in nitric oxide inhibition induced-hypertension.
    Rincón J; Correia D; Arcaya JL; Finol E; Fernández A; Pérez M; Yaguas K; Talavera E; Chávez M; Summer R; Romero F
    Life Sci; 2015 Mar; 124():81-90. PubMed ID: 25623850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between nitric oxide and angiotensin II in the endothelium: role in atherosclerosis and hypertension.
    Schulman IH; Zhou MS; Raij L
    J Hypertens Suppl; 2006 Mar; 24(1):S45-50. PubMed ID: 16601573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Selected components of the kallikrein-kinin system and of the renin-angiotensin-aldosterone system in offspring of parents with hypertension].
    Marzecka J
    Ann Acad Med Stetin; 1996; 42():123-38. PubMed ID: 9199117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems.
    Dielis AW; Smid M; Spronk HM; Hamulyak K; Kroon AA; ten Cate H; de Leeuw PW
    Hypertension; 2005 Dec; 46(6):1236-42. PubMed ID: 16286563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The renin-angiotensin and the kallikrein-kinin systems.
    Campbell DJ
    Int J Biochem Cell Biol; 2003 Jun; 35(6):784-91. PubMed ID: 12676165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of chronic blockade of the kallikrein-kinin system on the development of hypertension in rats.
    Majima M; Katori M
    Hypertension; 2001 Oct; 38(4):E21-3. PubMed ID: 11641321
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor necrosis factor-α, kidney function, and hypertension.
    Mehaffey E; Majid DSA
    Am J Physiol Renal Physiol; 2017 Oct; 313(4):F1005-F1008. PubMed ID: 28724611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced activity of the kallikrein-kinin system predominates over renin-angiotensin system overactivity in all conditions of sodium balance in essential hypertensives and family-related hypertension.
    Sànchez R; Nolly H; Giannone C; Baglivo HP; Ramírez AJ
    J Hypertens; 2003 Feb; 21(2):411-7. PubMed ID: 12569273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic targets and prototype therapeutics in the kallikrein-kinin system: bradykinin receptor agonists or antagonists.
    Sharma JN; Al-Sherif GJ
    ScientificWorldJournal; 2006 Oct; 6():1247-61. PubMed ID: 17041716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Kallikrein-kinin in hypertension].
    Omata K
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():228-33. PubMed ID: 15171374
    [No Abstract]   [Full Text] [Related]  

  • 15. The central nervous system and inflammation in hypertension.
    Marvar PJ; Lob H; Vinh A; Zarreen F; Harrison DG
    Curr Opin Pharmacol; 2011 Apr; 11(2):156-61. PubMed ID: 21196131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [NO and hypertension].
    Hirata Y
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():243-6. PubMed ID: 15171377
    [No Abstract]   [Full Text] [Related]  

  • 17. Significance of kallikrein-kinin and renin-angiotensin systems in the hypotensive mechanism of angiotensin-I converting enzyme inhibitors in essential hypertensives.
    Iimura O; Shimamoto K
    Adv Exp Med Biol; 1989; 247A():39-48. PubMed ID: 2532450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular interactions of vasoactive systems in cardiovascular damage.
    Bader M
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S7-9. PubMed ID: 11811382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential hypertension: is there a role for inflammatory mechanisms?
    Androulakis ES; Tousoulis D; Papageorgiou N; Tsioufis C; Kallikazaros I; Stefanadis C
    Cardiol Rev; 2009; 17(5):216-21. PubMed ID: 19690472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The renal kallikrein-kinin system: its role as a safety valve for excess sodium intake, and its attenuation as a possible etiologic factor in salt-sensitive hypertension.
    Katori M; Majima M
    Crit Rev Clin Lab Sci; 2003 Feb; 40(1):43-115. PubMed ID: 12627748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.